A New Era of Accountability for Medical Device Cybersecurity
In the past, cybersecurity issues in medical devices were considered technical oversights—correctable, internal, and largely shielded from public scrutiny. But in 2025, the U.S. Department of Justice (DOJ) issued a stark warning to the healthcare technology sector: cybersecurity failures can now lead to legal action.
That warning came in the form of a $9.8 million False Claims Act settlement with genomic sequencing giant Illumina. The enforcement wasn’t triggered by a breach, ransomware, or a data leak. It was based on allegations that the company misrepresented its cybersecurity capabilities when selling sequencing platforms to federally funded institutions.
This case represents a seismic shift in how the U.S. government views cybersecurity—not as an IT problem, but as a contract enforcement issue and a public safety concern.
What the DOJ Alleged
The DOJ’s complaint alleged that Illumina knowingly sold diagnostic platforms to federal agencies with undisclosed cybersecurity vulnerabilities—including the MiSeq Dx and NextSeq 550Dx systems.
Specifically, the government alleged that:
- Illumina did not incorporate secure design or lifecycle management practices into its software.
- It lacked an adequate product cybersecurity program and quality system.
- The company falsely certified compliance with industry cybersecurity standards such as ISO 27001 and the NIST Cybersecurity Framework, which were required under certain procurement terms .
These claims were enough to trigger an investigation and ultimately a settlement—despite the fact that no actual data breach occurred.
“The United States contends that the claims to the Agencies were false, regardless of whether any actual cybersecurity breaches occurred…” — DOJ Settlement Agreement
Illumina denied the allegations and did not admit liability in the settlement, but agreed to pay $9.8 million, with $4.3 million designated as restitution.
Why This Case Matters
This case is one of the clearest examples yet of the DOJ using the Civil Cyber-Fraud Initiative (CCFI) to target vendors who allegedly fail to meet cybersecurity requirements tied to government contracts.
The initiative was launched to ensure that organizations receiving federal funds—including healthcare providers, diagnostics vendors, and device manufacturers—are truthful in their cybersecurity representations.
It’s a shift from reactive enforcement (after a breach) to proactive prosecution of false claims, inadequate cybersecurity programs, and negligent system design.
From Regulatory Compliance to Legal Liability
In the FDA world, cybersecurity has become tightly integrated into regulatory guidance. The agency’s 2025 final guidance on premarket submissions requires manufacturers to:
- Implement a Secure Product Development Framework (SPDF)
- Provide threat modeling
- Validate security controls
- Maintain postmarket surveillance
But what the Illumina case shows is that regulatory compliance is no longer the end of the road. A manufacturer may clear the FDA’s bar and still find itself in legal jeopardy if its cybersecurity documentation, certifications, or marketing claims don’t match reality.
This risk is especially acute for companies doing business with:
- The Department of Veterans Affairs (VA)
- The Department of Defense (DoD)
- National Institutes of Health (NIH)
- Hospitals or labs receiving CMS or federal grant funding
Patient Safety at the Core
Why is this happening? Because cybersecurity lapses aren’t just technical. They increasingly represent a threat to patient safety.
Imagine a sequencing platform that receives a malicious update because secure boot is missing. Or a diagnostic device that can be remotely tampered with due to hardcoded credentials. These scenarios can lead to:
- Incorrect diagnoses
- Treatment delays
- Data corruption in clinical workflows
Healthcare cybersecurity is now recognized as clinical risk, not just compliance risk. The DOJ has picked up on that—and they’re acting accordingly.
What Medical Device Makers Must Do
If your company develops, sells, or services connected medical devices or diagnostic platforms—especially into government or research healthcare settings—here’s how to respond:
1. Review All Cybersecurity Claims
Go back through your FDA submissions, procurement documents, and commercial contracts. Ensure that your cybersecurity claims are not overstated or outdated.
2. Build a True SPDF
Don’t just document a secure product development lifecycle—live it. Integrate secure coding, SBOM tracking, code signing, and secure update mechanisms from day one.
3. Conduct Penetration Testing
Real testing, by third-party experts, not just vulnerability scans. These findings should feed into your risk assessment and mitigation strategy.
4. Align Legal, Engineering, and Quality Teams
The biggest risk in most companies? Departments working in silos. Sales signs off on cybersecurity promises that engineering can’t fulfill. This is how False Claims exposure begins.
5. Prepare for Oversight
Whether from FDA, OIG, or DOJ, enforcement is rising. Show that you’ve taken meaningful steps to protect patient data, system integrity, and contractual obligations.
Blue Goat Cyber’s Perspective
We’ve worked with device makers across diagnostics, wearables, and implantables. We’ve helped clients navigate FDA guidance, develop SPDF-aligned security processes, and uncover vulnerabilities in systems already in production.
The Illumina case is a clear sign: You need provable, documented, and functional cybersecurity programs—not just language in a slide deck or SOP.
If your device is being used in a hospital, research lab, or any federally funded setting, you are accountable—even without a breach.
Final Thoughts
The DOJ has changed the rules. Cybersecurity missteps can now cost millions in penalties and damage your brand reputation beyond repair.
Illumina may be the first, but it won’t be the last.
Ready to Take Control of Your Cyber Risk?
Blue Goat Cyber offers penetration testing, SBOM validation, SPDF alignment, and cybersecurity gap assessments tailored for FDA- and government-facing medical device firms.
Let’s secure your device—before someone else investigates it. Schedule a free consultation with us today.